| Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma RS Finn, S Qin, M Ikeda, PR Galle, M Ducreux, TY Kim, M Kudo, V Breder, ... New England Journal of Medicine 382 (20), 1894-1905, 2020 | 4723 | 2020 |
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ... The Lancet 389 (10088), 2492-2502, 2017 | 3955 | 2017 |
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a … H Wilke, K Muro, E Van Cutsem, SC Oh, G Bodoky, Y Shimada, ... The lancet oncology 15 (11), 1224-1235, 2014 | 2459 | 2014 |
| Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein M Ohh, CW Park, M Ivan, MA Hoffman, TY Kim, LE Huang, N Pavletich, ... Nature cell biology 2 (7), 423-427, 2000 | 1944 | 2000 |
| Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority … SY Jeong, JW Park, BH Nam, S Kim, SB Kang, SB Lim, HS Choi, DW Kim, ... The Lancet Oncology 15 (7), 767-774, 2014 | 1015 | 2014 |
| Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib SW Han, TY Kim, PG Hwang, S Jeong, J Kim, IS Choi, DY Oh, JH Kim, ... Journal of clinical oncology 23 (11), 2493-2501, 2005 | 989 | 2005 |
| Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies TY Kim, DW Kim, JY Chung, SG Shin, SC Kim, DS Heo, NK Kim, YJ Bang Clinical cancer research 10 (11), 3708-3716, 2004 | 949 | 2004 |
| Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy … YS Hong, BH Nam, K Kim, JE Kim, SJ Park, YS Park, JO Park, SY Kim, ... The lancet oncology 15 (11), 1245-1253, 2014 | 428 | 2014 |
| Optimization of patient selection for gefitinib in non–small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt … SW Han, TY Kim, YK Jeon, PG Hwang, SA Im, KH Lee, JH Kim, DW Kim, ... Clinical Cancer Research 12 (8), 2538-2544, 2006 | 330 | 2006 |
| Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis B Keam, SA Im, KH Lee, SW Han, DY Oh, JH Kim, SH Lee, W Han, ... Breast Cancer Research 13, 1-7, 2011 | 297 | 2011 |
